Initial Characteristics of the Patients Included in APL 93 Trial According to Induction Treatment
| . | ATRA → CT Group . | ATRA + CT Group . | High WBC Group . | Elderly Group . |
|---|---|---|---|---|
| No. of patients | 109 | 99 | 163 | 42 |
| Male gender | 52 (48%) | 52 (50%) | 84 (52%) | 22 (52%) |
| Age (yrs) | 45 (2-64) | 43 (7-63) | 42 (1-73) | 69 (65-77) |
| WBC count (109/L) | 1.3 (0.3-4.7) | 1.4 (0.3-4.8) | 15.9 (5.1-97.6) | 1.25 (0.5-46) |
| Platelet count (109/L) | 38 (4-249) | 34 (3-215) | 24 (2-164) | 33.5 (4-252) |
| Circulating blasts (109/L) | 0.25 (0-4) | 0.28 (0-3.3) | 13.35 (0-96.6) | 0.23 (0-19.8) |
| Microgranular variant M3 | 7 (6%) | 5 (5%) | 40 (24%) | 2 (5%) |
| Fibrinogen level (g/L) | 1.9 (0.2-7) | 1.7 (0.3-6.5) | 1.4 (0-7.4) | 1.9 (0.4-5.4) |
| . | ATRA → CT Group . | ATRA + CT Group . | High WBC Group . | Elderly Group . |
|---|---|---|---|---|
| No. of patients | 109 | 99 | 163 | 42 |
| Male gender | 52 (48%) | 52 (50%) | 84 (52%) | 22 (52%) |
| Age (yrs) | 45 (2-64) | 43 (7-63) | 42 (1-73) | 69 (65-77) |
| WBC count (109/L) | 1.3 (0.3-4.7) | 1.4 (0.3-4.8) | 15.9 (5.1-97.6) | 1.25 (0.5-46) |
| Platelet count (109/L) | 38 (4-249) | 34 (3-215) | 24 (2-164) | 33.5 (4-252) |
| Circulating blasts (109/L) | 0.25 (0-4) | 0.28 (0-3.3) | 13.35 (0-96.6) | 0.23 (0-19.8) |
| Microgranular variant M3 | 7 (6%) | 5 (5%) | 40 (24%) | 2 (5%) |
| Fibrinogen level (g/L) | 1.9 (0.2-7) | 1.7 (0.3-6.5) | 1.4 (0-7.4) | 1.9 (0.4-5.4) |